
AKTS Stock Forecast & Price Target
AKTS Analyst Ratings
Bulls say
Aktis Oncology is a biotech company with a strong discovery platform focused on developing targeted treatments for solid tumors and has a partnership with another company. With a projected stock price of $35 and a value of $1.93 billion, the company is rated as OUTPERFORM due to its promising treatments for prostate and lung cancer and its innovative use of yeast display and DOTA. However, there are potential risks to consider, including negative clinical results and delays in regulatory approval.
Bears say
Aktis Oncology is well-positioned to experience significant growth in the next few years with their pipeline of targeted radiopharmaceutical therapies for solid tumors. However, the limited market for their products and strong competition from other biotech companies present major risks and challenges for the company's future success. Additionally, Aktis Oncology's financial position is concerning, with a high burn rate and a market cap that may not be enough to sustain operations until potential revenue in 2025.
This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
AKTS Analyst Forecast & Price Prediction
Start investing in AKTS
Order type
Buy in
Order amount
Est. shares
0 shares